Pituitary & hypothalamus

Hormonal staining patterns and clinical outcomes in acromegaly: a 15-year single-center study

PituitaryPublished Retrospective cohort study

Authors' conclusion

Despite higher proliferative activity, GH/PRL adenomas did not demonstrate inferior surgical or medical outcomes compared with GH-only adenomas. Prognosis appears to be driven primarily by anatomical features and cytokeratin patterns, supporting individualized treatment strategies.

Study context

Population
Patients with acromegaly who underwent transsphenoidal surgery, 2010–2025
Participants
90 patients
Exposure
GH/prolactin (PRL)-positive vs GH-only somatotroph adenomas
  • GH-onlyn = 47reference
  • GH/PRLn = 39
  • Othern = 4
Outcome
Postoperative remission
Methodological detailssingle-center
  • Single-center

Main finding

As reported in the abstract

Postoperative remission, overall

32

35.6%

Observational data: associations, not effects.

Further findings

Postoperative remission by optic chiasm compression (multivariable)

OR for remission (95% CI)P value
Optic chiasm compressionLower odds of remission; independently associated · multivariable analysis0.212 (0.049–0.910)P = 0.037

SSA response by perinuclear CK8/18 staining (multivariable)

OR for SSA response (95% CI)P value
Perinuclear CK8/18 stainingIndependently associated4.839 (1.198–19.540)P = 0.027

SSA response by T2-weighted MRI hypointensity (multivariable)

OR for SSA response (95% CI)P value
T2-weighted MRI hypointensityIndependently associated5.464 (1.284–23.250)P = 0.022

Biochemical response to SSA therapy

Patients receiving SSA therapy
45
Achieved biochemical response
25 (55.6%)

Ki-67

Ki-67 higher in GH/PRL adenomas, not associated with treatment outcomes

Original publication

Hormonal staining patterns and clinical outcomes in acromegaly: a 15-year single-center study. Pituitary. Published 18 May 2026. doi:10.1007/s11102-026-01688-4

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.